Viatris Inc. · NASDAQ:VTRS
Viatris — Mylan — Merger or Acquisition (June 2020)
12 slides from Viatris's merger presentation, Jun 2, 2020
Slide 1: VIATRIS: A New Champion for Global Health
June 2020 VIATRIS: A New Champion for Global Health TM
Slide 2: Forward-Looking Statements
This communication contains “forward-looking statements”. Such forward-looking statements may include, without limitation, statements about the proposed combination of Upjohn Inc. (“Newco”) and Mylan, which will immediately follow the proposed separation of the Upjohn business (the “Upjohn Business”
Slide 3: Additional Information and Where to Find It
Additional Information and Where to Find It This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale
Slide 4: Non-GAAP Financial Measures
Non-GAAP Financial Measures Mylan is not providing forward looking information for accounting principles generally accepted in the United States (“U.S. GAAP”) reported financial measures or a quantitative reconciliation of forward-looking non-GAAP financial measures to the most directly comparable U
Slide 5: Empowering people worldwide to live healthier, at every stage of life
Empowering people worldwide to live healthier, at every stage of life. PARTNERSHIP LEADERSHIP ACCESS
Slide 6: Substantial Merits of Mylan's Combination with Pfizer's Upjohn Business
Substantial Merits of Mylan’s Combination with Pfizer’s Upjohn Business Enhance our global scale and geographic reach. Accelerate Mylan’s own standalone business plan by at least 3-5 years. A few of the benefits we believe VIATRIS will deliver: Create an even stronger financial profile by Further st
Slide 7: VIATRIS Will Offer a Unique Global Healthcare Gateway
Empowering people worldwide to live healthier, at every stage of life Partner of Choice™ Creating better value for all stakeholders Global Supply Network Expansive Technical Expertise Cost Efficient Operating Platform Broad Global Commercial Reach Across Channels &TAs Global Healthcare GatewayTM VIA
Slide 8: Clear Roadmap of Execution to Optimize Total Shareholder Return
Clear Roadmap of Execution to Optimize Total Shareholder Return (TSR) Years 0 1 2 3 4 5 6 7+ Business Execution Capital Allocation Operations Leverage New Pipeline Launches Capital Return Synergies Business Development New Pipeline Investment INTEGRATION PRODUCT LAUNCHES ~$3bn COST SYNERGIES REVENUE
Slide 9: Expected Attractive Financial Profile
Expected Attractive Financial Profile Selected Spec Pharma / Generics VIATRIS Avg. Est. Gross Debt / 2020E EBITDA3 * Pays Dividend / Dividend Yield4 2020E EBITDA Margin2 * ~4x 30% 28% 28% 18% 23% 23% Market Cap ($bn) ≤ 2.5x Sustained leverage target ~40%5 * Non-GAAP measures. Please see slide 4. Sou
Slide 10: Highly Qualified Viatris Board of Directors
Highly Qualified Viatris Board of Directors Ian Read Former Chairman and CEO at Pfizer Current Director at Kimberly-Clark Corporation Richard A. Mark Current Mylan N.V. Director Former Partner at Deloitte & Touche LLP (“D&T”) Pauline van der Meer Mohr Current Mylan N.V. Director Former Sr. EVP and H
Slide 11: Deep Expertise from Both Legacy Companies
Deep Expertise from Both Legacy Companies The leadership team’s collaborative approach will leverage complementary strengths through the future integration and beyond Robert Coury Executive Chairman As Executive Chairman of VIATRIS, will lead the Board and strategic direction of the Company, includi
Slide 12: Commitment to Global Social Responsibility (GSR)
Commitment to Global Social Responsibility (GSR) Viatris’ greater scale will help accelerate our mission to serve the world’s changing healthcare needs and further support our commitment to providing greater access to medicines to more patients across the globe GSR Oversight Enhancements to Mylan’s